These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

138 related items for PubMed ID: 27167902

  • 1. Risperidone-induced extrapyramidal side effects: is the need for anticholinergics the consequence of high plasma concentrations?
    Schoretsanitis G, Haen E, Hiemke C, Gründer G, Stegmann B, Schruers KR, Veselinovic T, Lammertz SE, Paulzen M.
    Int Clin Psychopharmacol; 2016 Sep; 31(5):259-64. PubMed ID: 27167902
    [Abstract] [Full Text] [Related]

  • 2. Pharmacokinetic Drug-Drug Interactions of Mood Stabilizers and Risperidone in Patients Under Combined Treatment.
    Schoretsanitis G, Haen E, Gründer G, Stegmann B, Schruers KR, Hiemke C, Lammertz SE, Paulzen M.
    J Clin Psychopharmacol; 2016 Dec; 36(6):554-561. PubMed ID: 27811552
    [Abstract] [Full Text] [Related]

  • 3. Effect of smoking on risperidone pharmacokinetics - A multifactorial approach to better predict the influence on drug metabolism.
    Schoretsanitis G, Haen E, Stegmann B, Hiemke C, Gründer G, Paulzen M.
    Schizophr Res; 2017 Jul; 185():51-57. PubMed ID: 27993531
    [Abstract] [Full Text] [Related]

  • 4. Pharmacokinetic patterns of risperidone-associated adverse drug reactions.
    Schoretsanitis G, Stegmann B, Hiemke C, Gründer G, Schruers KR, Walther S, Lammertz SE, Haen E, Paulzen M.
    Eur J Clin Pharmacol; 2016 Sep; 72(9):1091-8. PubMed ID: 27376639
    [Abstract] [Full Text] [Related]

  • 5. Pharmacokinetic considerations in the treatment of hypertension in risperidone-medicated patients - thinking of clinically relevant CYP2D6 interactions.
    Paulzen M, Haen E, Gründer G, Lammertz SE, Stegmann B, Schruers KR, Walther S, Schoretsanitis G.
    J Psychopharmacol; 2016 Aug; 30(8):803-9. PubMed ID: 27251417
    [Abstract] [Full Text] [Related]

  • 6. Cytochrome P450-mediated interaction between perazine and risperidone: implications for antipsychotic polypharmacy.
    Paulzen M, Haen E, Hiemke C, Stegmann B, Lammertz SE, Gründer G, Schoretsanitis G.
    Br J Clin Pharmacol; 2017 Aug; 83(8):1668-1675. PubMed ID: 28160505
    [Abstract] [Full Text] [Related]

  • 7. Clinical response in a risperidone-medicated naturalistic sample: patients' characteristics and dose-dependent pharmacokinetic patterns.
    Paulzen M, Haen E, Stegmann B, Unterecker S, Hiemke C, Gründer G, Schoretsanitis G.
    Eur Arch Psychiatry Clin Neurosci; 2017 Jun; 267(4):325-333. PubMed ID: 27695935
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Pharmacokinetic considerations in antipsychotic augmentation strategies: How to combine risperidone with low-potency antipsychotics.
    Paulzen M, Schoretsanitis G, Stegmann B, Hiemke C, Gründer G, Schruers KRJ, Walther S, Lammertz SE, Haen E.
    Prog Neuropsychopharmacol Biol Psychiatry; 2017 Jun 02; 76():101-106. PubMed ID: 28302501
    [Abstract] [Full Text] [Related]

  • 11. Pharmacokinetics of risperidone in different application forms - Comparing long-acting injectable and oral formulations.
    Schoretsanitis G, de Leon J, Haen E, Stegmann B, Hiemke C, Gründer G, Paulzen M.
    Eur Neuropsychopharmacol; 2018 Jan 02; 28(1):130-137. PubMed ID: 29153926
    [Abstract] [Full Text] [Related]

  • 12. Biperiden and haloperidol plasma levels and extrapyramidal side effects in schizophrenic patients.
    Meszaros K, Lenzinger E, Hornik K, Schönbeck G, Hatzinger R, Langer G, Sieghart W, Aschauer HN.
    Neuropsychobiology; 1997 Jan 02; 36(2):69-72. PubMed ID: 9267855
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Predicting plasma concentration of risperidone associated with dosage change: a population pharmacokinetic study.
    Uchida H, Mamo DC, Pollock BG, Suzuki T, Tsunoda K, Watanabe K, Mimura M, Bies RR.
    Ther Drug Monit; 2012 Apr 02; 34(2):182-7. PubMed ID: 22377743
    [Abstract] [Full Text] [Related]

  • 16. Factors influencing concentrations of risperidone and 9-hydroxyrisperidone in psychiatric outpatients taking immediate-release formulations of risperidone.
    Guo Z, Chen C, Deng S, Lu H, Ni X, Zhang M, Huang S, Wen Y, Shang D, Wang Z.
    Hum Psychopharmacol; 2024 Jan 02; 39(1):e2886. PubMed ID: 37983624
    [Abstract] [Full Text] [Related]

  • 17. Effects of Shakuyaku-Kanzo-to on Extrapyramidal Symptoms During Antipsychotic Treatment: A Randomized, Open-Label Study.
    Ota T, Miura I, Kanno-Nozaki K, Hoshino H, Horikoshi S, Fujimori H, Kanno T, Mashiko H, Yabe H.
    J Clin Psychopharmacol; 2015 Jun 02; 35(3):304-7. PubMed ID: 25839338
    [Abstract] [Full Text] [Related]

  • 18. Therapeutic drug monitoring in children and adolescents with schizophrenia and other psychotic disorders using risperidone.
    Taurines R, Fekete S, Preuss-Wiedenhoff A, Warnke A, Wewetzer C, Plener P, Burger R, Gerlach M, Romanos M, Egberts KM.
    J Neural Transm (Vienna); 2022 Jun 02; 129(5-6):689-701. PubMed ID: 35303169
    [Abstract] [Full Text] [Related]

  • 19. Evaluation of Antipsychotic Dose Reduction in Late-Life Schizophrenia: A Prospective Dopamine D2/3 Receptor Occupancy Study.
    Graff-Guerrero A, Rajji TK, Mulsant BH, Nakajima S, Caravaggio F, Suzuki T, Uchida H, Gerretsen P, Mar W, Pollock BG, Mamo DC.
    JAMA Psychiatry; 2015 Sep 02; 72(9):927-34. PubMed ID: 26131622
    [Abstract] [Full Text] [Related]

  • 20. Antipsychotic-induced extrapyramidal syndromes. Risperidone compared with low- and high-potency conventional antipsychotic drugs.
    Schillevoort I, de Boer A, Herings RM, Roos RA, Jansen PA, Leufkens HG.
    Eur J Clin Pharmacol; 2001 Jul 02; 57(4):327-31. PubMed ID: 11549212
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.